Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GRFS 
Grifols SA ADR (GRFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: GRFS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.19
1 Year Target Price $12.19
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.11% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.55B USD | Price to earnings Ratio 19.26 | 1Y Target Price 12.19 |
Price to earnings Ratio 19.26 | 1Y Target Price 12.19 | ||
Volume (30-day avg) 2 | Beta 0.98 | 52 Weeks Range 6.09 - 10.96 | Updated Date 09/16/2025 |
52 Weeks Range 6.09 - 10.96 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 1.78% | Basic EPS (TTM) 0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4% | Operating Margin (TTM) 18.48% |
Management Effectiveness
Return on Assets (TTM) 4.43% | Return on Equity (TTM) 4.99% |
Valuation
Trailing PE 19.26 | Forward PE 10.66 | Enterprise Value 18164424120 | Price to Sales(TTM) 1.15 |
Enterprise Value 18164424120 | Price to Sales(TTM) 1.15 | ||
Enterprise Value to Revenue 2.08 | Enterprise Value to EBITDA 9.57 | Shares Outstanding 258224000 | Shares Floating 561059341 |
Shares Outstanding 258224000 | Shares Floating 561059341 | ||
Percent Insiders - | Percent Institutions 57.63 |
Upturn AI SWOT
Grifols SA ADR
Company Overview
History and Background
Grifols, founded in 1909 in Barcelona, Spain, is a global healthcare company and a leading producer of plasma-derived therapies. It initially focused on analytical laboratory services and expanded into pharmaceuticals and blood components. A key milestone was the development of plasma fractionation in the mid-20th century. The company has grown through acquisitions and global expansion.
Core Business Areas
- Plasma Fractionation: Extraction and purification of plasma proteins to create therapeutic products. This includes immunoglobulins, albumin, alpha-1 antitrypsin, and clotting factors.
- Hospital Division: Provides products and services for hospital pharmacies, including IV solutions, nutrition products, and medical devices.
- Diagnostic Division: Develops and manufactures diagnostic solutions for transfusion medicine, including blood typing reagents and diagnostic instruments.
- Bio Supplies Division: Grifols Bio Supplies focuses on biological materials for research and development for the biotech and pharmaceutical industries.
Leadership and Structure
Grifols is led by a board of directors and an executive management team. The organizational structure is divided into its core business divisions, with regional operations around the world.
Top Products and Market Share
Key Offerings
- Albumin: Albumin is used to treat fluid imbalance and volume loss. Grifols is a major global producer of albumin. The market share is significant, but specific numbers vary. Competitors include CSL Behring, Takeda, and Kedrion.
- Immunoglobulins (Ig): Immunoglobulins are used to treat immune deficiencies and autoimmune disorders. Grifols holds a substantial share of the global immunoglobulin market. Competitors include CSL Behring, Takeda, and Octapharma.
- Alpha-1 Antitrypsin (AAT): AAT is used to treat Alpha-1 antitrypsin deficiency, a genetic condition that can cause lung and liver disease. Grifols markets Prolastin-C for this deficiency and competes with CSL Behringu2019s Zemaira and Takedau2019s Aralast. Market share data is not publicly available
Market Dynamics
Industry Overview
The plasma-derived therapies industry is characterized by high barriers to entry due to regulatory requirements and the complexity of plasma fractionation. The industry is growing due to increasing demand for plasma therapies and advancements in research and development.
Positioning
Grifols is a leading player in the plasma-derived therapies market, with a strong global presence. Its competitive advantages include its extensive plasma collection network, advanced fractionation technology, and diverse product portfolio.
Total Addressable Market (TAM)
The global plasma fractionation market is expected to reach hundreds of billions of dollars. Grifols is well-positioned to capture a significant share of this market. Precise TAM value requires real-time market data, which is constantly fluctuating.
Upturn SWOT Analysis
Strengths
- Global presence
- Extensive plasma collection network
- Advanced fractionation technology
- Diversified product portfolio
- Strong brand recognition
Weaknesses
- High debt levels
- Dependence on plasma supply
- Vulnerability to regulatory changes
- Competition from larger players
- Geopolitical risks
Opportunities
- Growing demand for plasma therapies
- Expansion into emerging markets
- Development of new plasma-derived products
- Acquisitions of smaller players
- Technological advancements in plasma fractionation
Threats
- Fluctuations in plasma supply
- Increasing competition
- Regulatory changes
- Economic downturns
- Emergence of alternative therapies
Competitors and Market Share
Key Competitors
- CSL (CSLLY)
- Takeda Pharmaceutical (TAK)
- Octapharma
Competitive Landscape
Grifols competes with other major plasma-derived therapies companies. While CSL Behring may be larger in overall market capitalization, Grifols has specific advantages in certain product segments. Grifols needs to focus on debt reduction and strategic innovation to maintain its competitive edge.
Major Acquisitions
Biotest AG
- Year: 2022
- Acquisition Price (USD millions): 1100
- Strategic Rationale: This acquisition expanded Grifols' plasma supply and strengthened its presence in Europe.
Growth Trajectory and Initiatives
Historical Growth: Grifols has experienced significant growth over the past decade, driven by increasing demand for plasma therapies and strategic acquisitions. The company has expanded its global presence and diversified its product portfolio.
Future Projections: Future growth projections depend on analyst estimates and industry trends. The company is expected to continue to grow its revenue and earnings, driven by increasing demand for plasma therapies and its expansion into new markets.
Recent Initiatives: Recent initiatives include investments in research and development, expansion of plasma collection centers, and strategic acquisitions.
Summary
Grifols is a strong player in the plasma-derived therapies market with a global presence and diversified product portfolio. Its key strength lies in its extensive plasma collection network and fractionation technology. However, high debt levels and competition pose challenges. Strategic initiatives to reduce debt and drive innovation are crucial for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Financial Reports
- Industry Analysis Reports
- Market Research Data
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is approximate and may not be fully up-to-date. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Grifols SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2006-05-17 | CEO & Director Mr. Jose Ignacio Abia Buenache | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 23833 | Website https://www.grifols.com |
Full time employees 23833 | Website https://www.grifols.com | ||
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.